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ABSTRACT: Fluorinated nanoparticles have increasing applications,
but they are still challenging to prepare, especially in the case of water-
soluble fluorinated nanoparticles. Herein, a fluorine labeling strategy is
presented that is based on the conjugation of custom-made small
fluorinated building blocks, obtained by simple synthetic trans-
formations, with carboxylated gold nanoparticles through a convenient
phase-transfer process. The synthesis of four fluorinated building blocks
with different chemical shifts in 19F nuclear magnetic resonance and
varied functionalities is reported, along with their conjugation onto
nanoparticles. Fluorinated nanoparticles of small core size obtained by
this conjugation methodology and by direct synthesis presented high
transverse relaxation times (T2) ranging from 518 to 1030 ms, and a
large number of equivalent fluorine atoms per nanoparticle (340−1260 fluorine atoms), which made them potential candidates for
19F magnetic resonance related applications. Finally, nontargeted fluorinated nanoparticles were probed by performing in vivo 19F
magnetic resonance spectroscopy (19F MRS) in mice. Nanoparticles were detected at both 1 and 2 h after being injected. 19F MRI
images were also acquired after either intravenous or subcutaneous injection. Their fate was studied by analyzing the gold content in
tissues by ICP-MS. Thus, the present work provides a general fluorination strategy for nanoparticles and shows the potential use of
small fluorinated nanoparticles in magnetic-resonance-related applications.
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1. INTRODUCTION
Fluorine is a unique atom that combines small atomic size with
the highest electronegativity in the periodic table and forms
one of the strongest bonds with carbon in organic chemistry.1
It is also known to be highly hydrophobic and lipophobic, and
fluorination is usually a challenging synthetic transformation.2
Nonetheless, and despite its low occurrence in biological
environments, fluorine is a very interesting atom from a
(bio)medical perspective. For instance, in drug design, the
inclusion of fluorine atoms in selected positions of organic
molecules often substantially impacts the therapeutic perform-
ance of those molecules.3 Enhancement of pharmacokinetic
properties, metabolic stability, or increased cellular uptake are
among the most commonly reported fluorine effects on drug
candidates.4 Likewise, fluorinated dendrimers were recently
used for gene transfection because of such dendrimers’ ability
to accelerate endosomal escape and avoid degradation of the
genetic material before reaching the cytosol, as compared to
nonfluorinated tags.5 Moreover, organic fluorine does not
naturally occur in the human biological media for which it
constitutes an exciting label or reporter. The absence of
background signal allows for fluorinated species to be studied
unequivocally and quantitatively by magnetic resonance
spectroscopy related techniques, as long as sufficient local
fluorine concentration is available. As a reporter, 19F is a widely
used label to study protein and sugar6,7 or lipid8 interactions by
19F nuclear magnetic resonance (19F NMR). In addition, 19F
magnetic resonance imaging (19F MRI), based on imaging
exogenous fluorinated probes in vivo, is a versatile diagnosis
technique complementary to conventional 1H MRI.9 The lack
of fluorine background allows for the design of ratiometric10
and quantitative smart contrast agents11 that are difficult to
achieve for 1H MRI.12 However, the applicability of 19F MRI is
currently limited by the detection sensitivity of the MRI
technique and the need for a high local concentration of
fluorine, for which the design of highly fluorinated probes is an
active field of research.13−17
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Despite its interesting features, the prospects of fluorine in
nanoparticle (NP) design for nanomedicine are somehow
limited for several reasons, namely, (i) the high hydrophobicity
of fluorinated molecules, (ii) the sometimes challenging
synthesis of those, (iii) the need for high local concentration
of fluorine for magnetic resonance (MR) applications, and (iv)
the usually low relaxation times due to NP intrinsic structural
design. Thus, examples of fluorinated NPs composed of a
metal core and fluorinated ligands that are water soluble are
scarce in the literature.18−20 In this context and in the last
years, we and others have overcome the fluorine hydro-
phobicity challenge and prepared fluorinated inorganic nano-
particles that are totally or partially dispersible in water by
different strategies. Such fluorinated NPs have been utilized in
other nanomedicine related fields, such as to study protein
corona in complex environments,21,22 as potential contrast
agents in 19F MRI,18,23,24 or as vehicles for enzyme transport,
and delivery through fluorine-based interactions25−27 (Figure
1C D). The strategies we used so far to introduce fluorinated
moieties on the surface of inorganic NPs were either via the
direct synthesis of gold NPs from chloroauric acid in the
presence of custom-designed fluorinated-thiolated ligands and
sodium borohydride (Figure 1A),21−23 or by ligand exchange
on presynthesized quantum dots with fluorinated-thiolated
ligands to prepare fluorinated quantum dots (Figure 1B).25−28
These methods, although useful, are limited to thiol-binding
nanomaterials, and for the case of ligand exchange, a significant
excess of ligand is needed and full exchange is hardly ever
achieved.
To avoid these issues, researchers have based many
fluorinated formulations in the field of nanomedicine on the
encapsulation of highly hydrophobic perfluorocarbons in
emulsions of about 200 nm or larger.29 Nonetheless and
except for its role as a label for magnetic resonance (MR), to
benefit from the presence of fluorine, it needs to be exposed
(not encapsulated) to be able to interact with biointerfaces and
receptors,30 as has been recently demonstrated for fluorinated
polymer NPs.31 Hence, the development of fluorination
strategies for macro(bio)molecules and colloids for biomedical
applications that expose fluorine on their surface is an
interesting research field. The pursuit of more general synthetic
methods for fluorination of NPs would be useful to develop
new fluorinated NPs with potential applications in multiple
areas, as mentioned before. We present herein a simplified
synthetic tool for the preparation of fluorinated NPs based on
the conjugation of fluorinated building blocks of simple
preparation onto the surface of carboxylated NPs. Such
conjugation took place through a facile phase transfer protocol,
which rendered water-soluble fluorinated NPs with interesting
MR features. We showed that small core NPs obtained by
either conjugation or direct synthesis method convey a high
local content of fluorine per NP while allowing for the
coexistence of other functionalities on the NP’s surface. In
addition, we proved that fluorinated small gold NPs are
suitable candidates for in vivo 19F magnetic resonance
spectroscopy (19F MRS) and imaging (19F MRI) in mice.
2. RESULTS
2.1. Fluorine Conjugation onto NPs. The conjugation of
small and simple fluorinated amino-ending building blocks (F,
F/OH, F/N3, and PhF) on a model carboxylated gold NP
(NP-COOH) to prepare novel fluorinated NPs (NP+F, NP
+F/OH, NP+F/N3, and NP+PhF) was optimized (Figure 2).
A simple phase transfer method was used to bind fluorinated
building blocks onto NP-COOH, which also greatly simplified
the purification of the so-obtained NPs.
On the one hand, small gold NPs of about 3 nm in core
diameter functionalized with carboxyl moieties were chosen as
Figure 1. (A) Synthesis of fluorinated NPs by direct synthesis
method. (B) Synthesis of fluorinated quantum dots by ligand
exchange method. Summary of applications of fluorinated NPs in
(C) magnetic resonance field, such as contrast agents in 19F MRI and
as protein corona reporters in 19F NMR-based diffusion. (D)
Illustration of the use of fluorinate quantum dots as enzyme
encapsulation and delivery platforms.
Figure 2. (A) Scheme of the conjugation method onto NP-COOH
through a phase transfer process reported herein. (B) Structures of
fluorinated building blocks F, F/OH, F/N3, and PhF. (C) Illustration
of obtained NP+F, NP+F/OH, NP+F/N3, and NP+PhF.
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the model NP because of their simple synthesis and the
plethora of techniques available for their characterization,
especially for the use of NMR,32 which is useful for
determining the amount of fluorine incorporated through 19F
NMR. Commercially available thiol and carboxyl ending PEG
ligand (HS-PEG-COOH) was mixed with chloroauric acid in
the presence of sodium borohydride to afford NP-COOH with
a gold core radius rc of 1.54 ± 0.54 nm, after transmission
electron microscopy (TEM) analysis. These NPs were stored
in water until further use, and the concentration of the NP
solution was obtained from the gold content analysis by
inductively coupled plasma mass spectrometry (ICP-MS).
Additionally, by combining TEM with ICP-MS data, it was
possible to estimate that the number of ligands per NP-COOH
was 140, which corresponded to approximately 5 ligands per
nm2 of the NP’s surface. The good colloidal stability of the so-
obtained NPs was also assessed by ultraviolet−visible spec-
troscopy (UV−vis), which displayed a plasmon resonance
band at λ = 510 nm, as expected for that core size.
On the other hand, we synthesized fluorinated building
blocks with different chemical shifts in 19F NMR (NP+F and
NP+PhF) or that carry different functional groups (NP+F/
OH and NP+F/N3), prone to be derivatized if desired. Amino-
ending fluorinated small building blocks F, F/OH, and F/N3
were prepared by simple synthetic transformations from
phthalimide protected amino starting groups, and the
perfluorinated tert-butoxide moiety was introduced via a
Mitsunobu reaction to afford the final amino unprotected
products in two or three reaction steps. Building block PhF,
with a different fluorinated moiety, was obtained through the
reaction of a diamino derivative and a conveniently function-
alized acyl chloride. Except for the latter, the rest of the
fluorinated building blocks were volatile, and hence they were
stored in dichloromethane solution after reaction and workup.
The amount of each building block in solution was calculated
by 19F NMR calibration of the fluorine signal intensity with
respect to a fixed and known amount of trifluoroacetic acid
(Figures S1 and S2). All the synthetic and characterization
details are described in the Supporting Information.
These fluorinated building blocks presented an amino group
that could be readily reacted with carboxyl groups on the NP
surface through EDC/NHS activation. Such a methodology is
straightforward, compatible with both water and organic
solvents, and widely applied to the functionalization of NPs
with biomolecules because of the usually mild reaction
conditions.33,34 In our protocol, carboxylated NPs in water
were initially mixed with EDC/NHS and allowed to react for
30 min to activate the carboxyl groups on the NP surface.
Subsequently, the selected fluorinated building block in
dichloromethane (DCM) was added, and the mixture was
stirred vigorously to promote maximum contact between the
two immiscible phases, the red aqueous one containing the
NP-COOH and the transparent organic one with the selected
fluorinated compound. In our particular setting, because of the
fluorination of the NPs, a phase transfer takes place from the
aqueous to the organic phase, which is easily observed due to
the red color transfer from the top aqueous phase to the
bottom organic one. Such a process happened within the first
15 min after amine addition, but the reaction was allowed to
stir overnight to achieve the maximum conjugation yield.
The reaction conditions were optimized for each building
block to obtain the highest conjugation yield, defined as the
percentage of ligands functionalized with fluorinated building
blocks per each NP. However, with this system, a maximum
conjugation yield for each building block was achieved no
matter how much amine was added (27−51%, Table 1), most
likely due to steric hindrance of the already conjugated
fluorinated building blocks that may hamper the inclusion of
new ones. The increase in the EDC/NHS amount did not
improve the yield, and in some cases, it even led to partial
aggregation of the gold nanoparticles, as observed by UV−vis
(Table 1, entry 1). Frequently, this type of conjugation takes
place under more or less mild basic conditions. However, the
use of a buffered solution at pH 9 did not have a clear positive
impact on the yield of the reaction (Table 1, entry 4 vs 5).
2.2. Characterization of Fluorinated NPs Obtained by
the Conjugation Method. After the synthesis, NP+F, NP
+F/OH, NP+F/N3, and NP+PhF were purified by phase
separation, and the now transparent aqueous layer was
discarded. The fluorinated NPs were in the organic phase
after the reaction, so dichloromethane was removed by
evaporation. The dried, fluorinated NPs were easily redis-
persed in water and extensively washed through filtration to
remove all reagents and unbound fluorinated building blocks
(Figure S3). The dual solubility of the so-obtained NPs, which
could be both dispersed in dichloromethane and water, was
enabled by the 3 kDa PEG linker present in the ligand
structure. The absence of unbound fluorinated building blocks
was confirmed by 19F NMR, taking advantage of the different
chemical shifts of the fluorine atoms in the free building blocks
(δ = −71.87 ppm (F); −71.71 ppm (F/OH); −71.89 ppm (F/
N3); −62.73 ppm (PhF)) and in the corresponding fluorinated
NPs (δ = −71.41 ppm (NP+F); −71.38 ppm (NP+F/OH and
NP+F/N3); −63.61 ppm (NP+PhF)) (Figure 3A). Sub-
sequently, thorough characterization by different techniques
was performed. UV−vis spectra showed minimal variations
between the parent NP-COOH and the newly obtained
fluorinated NPs, and all surface resonance plasmon (SPR)
wavelengths ranged from 509 to 511 nm (Figure 3B). This
feature means that the optimized conjugation conditions did
not affect the core of the NPs. This was further confirmed by
TEM analysis that showed that the cores’ sizes remained
unchanged after the conjugation (Figure 3C, D). Diffusion
Table 1. Selection of Conjugation Conditions Testeda
entry Fc resulting NP yield (%)d
1b 0.1 NP+F e
2 0.3 NP+F e
3 0.4 NP+F 38
4 0.9 NP+F 36
5 0.9 NP+F 39f
6 0.4 NP+F/OH 15
7 0.6 NP+F/OH 27
8 0.4 NP+F/N3 35
9 0.6 NP+F/N3 51
10 0.4 NP+PhF 14f
11 0.8 NP+PhF 47
a286 equiv. of EDC with respect to COOH moles and 3 NHS
equivalents with respect to EDC were used in each reaction. b857
equiv. of EDC were used. cF refers to fluorinated building block
equivalents with respect to EDC. dPercentage of ligands modified
with fluorinated building blocks in each NP. eAggregation detected by
UV−vis. fBorate buffer saline (BBS buffer) at pH 9 was used in the
aqueous phase.
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ordered spectroscopy (DOSY) measurements were performed
to calculate the diffusion coefficient of NPs in water before and
after conjugation. From the diffusion coefficient and through
the Einstein−Stokes relation, it was possible to calculate the
hydrodynamic size of each NP (Figure 3C, E).21,22,32 It was
observed that the conjugation of F and PhF produced a size
increase of 2 nm in the hydrodynamic radius (rh) as compared
to the size of NP-COOH (rh = 13.53 nm), and the conjugation
of branched more bulky F/OH and F/N3 afforded an extra size
increase of 3.54 and 2.65 nm, respectively (Figure 3C and
Table S3). The data obtained from DOSY agreed with those
obtained from dynamic light scattering (DLS) (Figure S7).
We studied the storage stability of the so-obtained
fluorinated NPs over time from two points of view, that is
leaching of fluorine and changes in hydrodynamic size. For this
reason, 19F NMR spectra of one-year-old samples were
performed, and neither changes in the fluorine conjugation
ratio nor the appearance of new signals were detected because
of the degradation of fluorinated moieties. Also, DLS
measurements were performed on the same samples, and it
was observed that NPs remained mostly unchanged in terms of
hydrodynamic size. It must be noted that samples were not
submitted to any particular stability test and instead were
simply stored between 4 °C and room temperature for about
one year (Table S3). Also, XPS measurements showed the
presence of Au (0), Au−S bonds, and fluorine. However,
penetration depth limitations of the technique and the thick
organic coating on the NPs did not allow us to rule out the
presence of small amounts of oxidized gold or sulfur species
(see Figure S8).
2.3. Magnetic Resonance Properties of Fluorinated
NPs. We also studied whether the conjugated fluorinated
building blocks could afford fluorinated NPs with interesting
properties as labels for magnetic resonance derived applica-
tions. For this purpose, longitudinal (T1) and transverse (T2)
relaxation times of NP+F, NP+F/OH, NP+F/N3, and NP
+PhF were measured. Ideally, long T2 values are desirable to
avoid signal intensity loss, whereas short T1 values are
important to reduce acquisition times and increase the number
of scans per unit time. In our examples, we obtained T1 values
ranging from 812 to 997 ms and T2 values between 518 and
766 ms (Figure 4 and Table S5). For the longitudinal
relaxation times, our NPs are within the average values
reported for other fluorinated probes. Interestingly, the
transverse relaxation times are well above the average (Figure
Figure 3. (A) 19F NMR spectra of NP+F, NP+F/OH, NP+F/N3, and NP+PhF. (B) UV−vis spectra of NP-COOH, NP+F, NP+F/OH, NP+F/
N3, and NP+PhF. (C) Graph showing the core radius (rc) and the hydrodynamic radius (rh) of each NP as obtained from TEM or DOSY analysis,
respectively. (D) TEM micrographs of all NPs showing the gold cores, scale bar corresponds to 50 nm. (E) DOSY spectra for all NPs, showing that
all signals in the spectra belong to the NPs and the diffusion coefficient for each NP.
Figure 4. (A) Illustration of NP-F and NP-PhF, obtained by direct
method synthesis. (B) Plot of the T1, T2, and fluorine atoms (F
atoms) per NP for each NP. For relaxation times, the mean and
standard deviation of two independent measurements are shown.
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S12). Considering the highest conjugation yield achieved for
each of them and knowing from ICP-MS data that each NP
had 140 ligands, we could estimate the number of fluorine
atoms per NP, which ranged from 340 to 643 and represents
the localized amount of equivalent fluorine atoms that a single
NP conveys by itself, as long as it remains intact.
For comparison purposes, similar fluorinated NPs already
reported by us (NP-F and NP-PhF) were prepared by the
direct synthesis method (Figure 1A) and shown in Figure
4A.21−23 The so-obtained NPs were very similar in core size (rc
= 1.47 ± 0.43 nm (NP-F) and 1.60 ± 0.45 nm (NP-PhF)) to
those obtained by the conjugation method and slightly smaller
in hydrodynamic size because of the shorter length of the
employed ligands (rh = 8.99 ± 0.07 nm (NP-F) and 9.82 ±
0.10 nm (NP-PhF)). The ligand density for both NPs was also
around 5 ligands per nm2 of gold core surface, as obtained by
ICP-MS analysis. Using the direct synthesis method with
already synthesized fluorinated PEGylated ligands (Scheme
S5), all ligands on the surface of the NPs were fluorinated.
Hence, by this method, we could achieve fluorine loadings of
up to 840 and 1260 atoms per NP-PhF and NP-F, respectively.
The relaxation times obtained for these NPs were higher for
NP-F (T1 = 1161 ms and T2 = 1030 ms) and quite similar for
NP-PhF but higher in general (T1 = 849 ms and T2 = 777 ms)
when compared with those obtained for NPs prepared by
conjugation method (Figure 4B and Table S5).
2.4. In Vivo 19F MRS and 19F MRI Experiments. To test
the potential in vivo applicability of small fluorinated NPs of
the type described herein in terms of 19F signal detection, we
injected three mice with a selected fluorinated NP and in vivo
nonlocalized 19F MRS (magnetic resonance spectroscopy) was
performed. As we did not have any previous reference work for
the in vivo use of such NPs and being SNR (signal-to-noise
ratio) one of the significant limitations of 19F-based MR
detection, we chose the most favorable scenario, that is, the use
of a fully fluorinated gold NP that maximized the fluorine
atoms per NP (NP-F with 1260 F atoms/NP) and a high
concentration of those NPs (18 μM in NPs, approximately 23
mM in fluorine). NP-F was prepared as described previously
by us,21−23 with a gold core radius rc of 1.47 ± 0.43 nm as
obtained by TEM (Figure 5G), and a hydrodynamic radius rh
of 8.99 ± 0.07 nm as measured by DOSY. The UV−vis
spectrum showed the typical surface plasmon band at 511 nm,
which is expected for this size of NP, and displayed colloidal
stability. The concentration of NP-F solution was measured by
ICP-MS to obtain the gold content. The fluorine concentration
was obtained by assuming that each NP-F had around 140
ligands (approximately 5 ligands/nm2 of the NP’s surface), as
calculated herein (see the Supporting Information) and
previously,21−23 and by combining these data with the NP
concentration obtained by ICP-MS. As expected, NP-F
displayed a single narrow peak in 19F NMR with a chemical
shift δ of −71.36 ppm (Figure 5H) and had T1 and T2 values
around 1 s, as shown previously (Figure 4B).
The aim of this experiment was to test the possibility of a 19F
signal detection in vivo by using our fluorinated NPs, so no
targeting was introduced in NP-F and no particular tissue was
selected for spectroscopy. Instead, we performed 19F MRS of
the bottom half of the mice at 1 and 2 h after intravenous
injection in the tail. That area was selected on the basis of the
assumption that NPs would mostly be eliminated through
either hepatobiliary or renal excretion pathways. In all three
mice, we observed a clear peak corresponding to our NPs at 1
and 2 h after injection, as NPs accumulated in tissues (Figure
5A). Each spectrum was obtained in about 16 min, although
the signal could be already detected after a few scans, and the
mice were not moved between the first and second scan. The
SNR increased between the first and second scan, as one could
expect because of the increased accumulation of NPs in tissues,
and it was particularly noticeable in two of the three mice
Figure 5. (A) 19F MRS spectra of three mice injected with NP-F 1−2 h after injection. An exponential line broadening of 15 Hz was applied to all
spectra when analyzed in Mnova. (B) SNR of each spectrum as obtained with the Mnova software SNR tool. (C) MRI phantom image of NP-F at
three different concentrations of fluorine: (1) 21, (2) 15, and (3) 1.5 mM. The rest of the tubes contained water. (D) MRI images after
subcutaneous localized back injection of NP-F (21 mM in fluorine). The yellow arrow on the 1H MRI image shows the injection site. The mouse’s
back was placed on the surface coil. (E) MRI image of the liver after tail vein injection of NP-F (21 mM in fluorine). The mouse’s belly was placed
on the surface coil. (F) ICP-MS analysis of the gold content of extracted tissues and fluids from three mice (liver, spleen, lungs, kidneys, blood, and
urine) represented in terms of gold content per unit weight of tissue or fluid. (G) TEM micrograph of NP-F. (H) 19F NMR spectra of NP-F.
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(Figure 5B). It must be noted that the NPs employed in this
study and those reported in this paper have chemical shifts that
do not interfere with signals around −80 ppm coming from
isoflurane and metabolites derived from it, which is a
commonly used fluorinated anesthetic drug. After the last
scan, mice were sacrificed, and several tissues and fluids were
collected, namely liver, spleen, lungs, kidneys, blood, and urine.
After lyophilization, the extracted tissues and fluids, together
with the gold NPs in them, were digested first with nitric acid
and later with aqua regia, and the gold content was analyzed by
ICP-MS. The highest amount of gold in absolute numbers was
detected in the spleen and liver (Figure S13). However, the
organ’s amount of gold per weight was substantially larger for
the spleen than for the liver (Figure 5F). Interestingly, there
were still gold NPs detected in extracted blood, showing that
the circulating times exceeded 2 h for these NPs (Figure 5F
and Figure S13).
Subsequently, we tested the performance of NP-F as 19F
MRI contrast agents. Phantoms of NP-F solutions at different
concentrations (21, 15, and 1.5 mM in fluorine) were
prepared. A 7 T MRI scanner with a surface quadrature coil
was used for data acquisition, and hence sensitivity was greater
for the samples closer to the coil. More concentrated solutions
(21 and 15 mM) were already detectable after 1 min scan
(Figure S14), but after 2 h, even the 1.5 mM solution was
slightly noticeable (Figure 5C). Initially, for the in vivo
experiments, an NP-F localized subcutaneous injection on the
mouse’s back was performed, followed by imaging acquisition.
NPs were already detected after a very short scanning time (4
min) using this surface coil placed on the injection site and a
FLASH sequence (Figure 5D). Longer acquisition times
provided better SNR, as shown in Figure S15. Subsequently,
intravenous injection in the tail vein led to a nontargeted
biodistribution of NP-F. As expected, 1 h after injection partial
accumulation in the liver was already detectable using the same
surface coil placed on the mouse’s belly and a FLASH
sequence after 14 min of acquisition (Figure 5E).
3. DISCUSSION
Many NP synthetic methods are based on precoating
strategies, after which NPs are functionalized by ligand
exchange or polymer coating.35 To avoid the waste of costly
and sometimes synthetic challenging fluorinated ligands, we
developed a method based on the use of small, easy-to-prepare
fluorinated building blocks, based on commercially available
perfluorinated tert-butanol to avoid complex fluorination steps
and their conjugation onto preformed carboxylated NPs. By
customized design of the fluorinated building blocks (F, F/
OH, F/N3, and PhF), our methodology allowed the
preparation of fluorinated NPs with substantially different
chemical shifts in 19F NMR (NP+F and NP+PhF) or the
simultaneous introduction of other functional groups (NP+F/
OH and NP+F/N3). This methodology enabled the
conjugation of at least 340 fluorine atoms per NP and up to
643 fluorine atoms (Table S5). The employed reaction
conditions and phase transfer process were mild and did not
affect the colloidal stability of the resulting fluorinated NPs. A
number of NMR based techniques were used to characterize
them, such as the fluorine content through 19F NMR signal
integration or the hydrodynamic size by DOSY. It must be
noted that the so-obtained fluorinated NPs had exceptionally
high T2 values (above 500 ms), above the average of reported
fluorinated probes, which makes them potentially interesting as
fluorinated probes for 19F MRI. On the contrary, obtained T1
values were within the average of reported systems, although
ideally shorter times would be of greater interest (Figure S12).
The direct synthesis method previously reported by us
produced fluorinated NPs (NP-F and NP-PhF)21,22 of similar
size, colloidal stability, and MR properties as those reported
herein, but with higher fluorine content per NP, as all the
ligands on the surface were fluorinated. Regarding the
relaxation times, NP-F obtained by direct synthesis afforded
higher values for both T1 and T2, and NP-PhF had relaxation
time values more similar to those obtained for NPs prepared
by conjugation method, although still higher in general (Figure
S9B). Nonetheless, although the obtained T1 values are within
the average of reported values, the high T2 values of the
fluorinated NPs presented herein are usually hard to achieve
for fluorinated probes and are most likely a consequence of 2
factors: (i) the presence of PEG ligands that conferred water
solubility and high flexibility to the fluorine moieties, and (ii)
the small size of the gold core that provides sufficient curvature
to its surface to enable fluorine mobility. It must be noted that
although in the direct synthesis method all the ligands on the
NP surface had the same length, in the NPs obtained by the
conjugation method, NP+F, NP+F/OH, NP+F/N3, and NP
+PhF, the fluorinated building blocks protrude from the NP
because they form longer ligands than only HS-PEG-COOH.
This effect might provide some space for the fluorine atoms to
avoid the surrounding water and perhaps hide in more or less
hydrophobic pockets that could be formed in the outer shell of
the NPs. This could afford a plausible explanation for the lower
relaxation times of NPs prepared by conjugation of fluorinated
building blocks with respect to their sister NPs obtained by
direct synthesis, despite being all of them very similar in terms
of physical features and structure.
The applicability of fluorinated small gold NPs in MR
related techniques, beyond the characterization of essential
parameters such as the relaxation times, was evaluated. In this
sense, NP-F was successfully detected in vivo in three mice by
19F MRS. As a proof of concept and given the lack of targeting
of NP-F, very high fluorine concentrations were used. Also, 19F
MRI images were obtained within very reasonable scanning
times both after localized subcutaneous injection and after
systemic injection, as they started to accumulate in the liver.
Because the signal was already clearly detected both by 19F
MRS and 19F MRI after a few scans, we envisage that lower
systemic doses will be required for targeted, localized
spectroscopy/imaging in a pathological animal model.
However, that is yet to be tested. The biodistribution profile
was the expected for nontargeted NPs in healthy mice. We
believe that spleen and liver accumulation might be reduced in
the future by reducing the injected dose, which was
substantially high, and by slightly decreasing the hydrodynamic
size of NP-F. The detection of gold by ICP-MS in blood after
more than 2 h suggests that NP-F could have reasonable
circulating times, as has been generally observed for PEGylated
NPs, which is a promising feature for their applicability in vivo,
although it needs to be further explored.
4. CONCLUSION
The fluorine conjugation strategy reported herein poses an
alternative for the fluorination of other nanomaterials in which
efficient direct synthesis with fluorinated ligands is not possible
because of either challenging fluorinated ligand design or NP
synthetic method limitations. Thus, given the plethora of
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carboxylated NPs in the literature, the presented methodology
could be considered as a general method for fluorination of
NPs, particularly when exposure of the fluorine on the surface
is required. However, because of the different ligand
composition and structures of other reported carboxylated
NPs, we envisage that the conjugation process and purification
may have to be optimized and adapted for each particular case.
By simplifying the fluorination strategy and adapting it to the
modification of such a common functional group as the
carboxyl moiety, the possibility to extend this methodology to
label any kind of NP (not only gold-based), nanosystems or
macromolecules is now open, as long as they have carboxyl
groups available. Thus, nanomaterials with new surface designs
and applications could be produced, beyond the nanomedicine
field. Moreover, we proved that NPs of the types reported
herein can be used for in vivo 19F MRS and 19F MRI. Although
preliminary, these results set the pavement for future
applications of fluorinated NPs in vivo, but more detailed
studies are yet to be conducted before their use as diagnosis
tools in 19F MR related techniques. For this particular field of
application, the use of small core-sized NPs along with
PEGylated ligands was key to achieving high probe
concentrations and good relaxation times for fluorine.
5. EXPERIMENTAL SECTION
All experimental procedures are fully described in detail in the
Supporting Information. Here we include a few representative
procedures.
Fluorine Conjugation Method for the Preparation of NP+F.
Typical Procedure. NP-COOH in MilliQ water (690 μL, 0.33 μM)
was placed in a screw capped vial with a magnet. A solution of NHS in
water (3.21 mg in 25 μL) was added onto NP-COOH followed by a
solution of EDC·HCl in water (1.78 mg in 25 μL). The mixture was
allowed to stir capped at r.t. for 30 min to activate carboxyl groups.
CH2Cl2 (263 μL) was then added to the activated NPs followed by
building block F dissolved in CH2Cl2 (82 μL, 47.7 mM), and the
reaction was tightly capped to avoid solvent evaporation. The reaction
was allowed to stir at the maximum possible speed at r.t. After 15 min,
the phase transfer of the NPs from the aqueous phase to the organic
already took place; however, the reaction was left stirring overnight to
achieve the maximum conjugation possible. The next morning, the
reaction mixture was transferred to an Eppendorf and centrifuged for
a short time to improve phase separation. Following this procedure,
the organic phase was washed twice with water and then transferred
to a glass vial and left open to evaporate. In this step, most of
unreacted building block F also evaporated. A flush of compressed air
was used to finally ensure that all CH2Cl2 was gone and then the
resulting NPs were resuspended in MilliQ water. This solution was
transferred to 100 kDa MWCO amicon filters and washed thoroughly
(at least seven times) with MilliQ water to render NP+F.
Direct Synthesis Method for the Preparation of NP-F.
Typical Procedure. HS-PEG-F ligand (1125 μL of a 2.5 mM
solution in CH2Cl2) was added to 50 mL of CH2Cl2 while stirring at
r.t. Subsequently, a 0.1 M solution of NaBH4 was freshly prepared
with ice-cold methanol and allowed to stand for 1 min. During that
minute, a freshly prepared solution of HAuCl4 (250 μL, 25 mM) in
ice-cold methanol was added to the reaction mixture. One minute
after the preparation of NaBH4 solution, the latter (313 μL, 0.1 M)
was added dropwise to the ligand/gold mixture. The reaction was
stirred for 30 s and then allowed to stand overnight without stirring at
r.t. Hereby the solution was capped to avoid solvent evaporation. The
next day, the solvent was evaporated in a rotary evaporator, and the
NPs were resuspended in water and then purified by centrifugation.
First, NPs were centrifuged twice at 1.5 × 105 g for 2 h to remove
unbound ligand and very small NPs, which remained in the
supernatant and were discarded. Second, the so-obtained pellet was
resuspended in water and centrifuged twice at 5 × 104 g for 30 min to
remove aggregates and bigger NPs that precipitated at that speed and
were discarded. Hence, NPs that remained in the supernatant were
kept for further experiments. Prior to their use in vivo, NP-F was
concentrated down to 17 μM (NP concentration) in water using
centrifugal filters (100 kDa MWCO).
Transverse and Longitudinal Relaxation Times (T2 and T1)
Measurement of Fluorine. 19F T2 measurements were performed
using Bruker’s standard CPMG sequence at 470.55 MHz with the
following parameters: TR = 12.0 s, 16 echo times covering a range
between 0.02 and 24 s, SW = 17 ppm, NS = 24, DS = 4 and 32K
points. T1 measurements were performed using an inversion recovery
method with Bruker’s t1ir sequence at 470.55 MHz with the following
parameters: TR = 12.0 s, 16 inversion times (5, 4.5, 4, 3.5, 3, 2.5, 2,
1.5, 1, 0.800, 0.500, 0.300, 0.200, 0.100, 0.050, 0.001 in seconds), SW
= 20 ppm, NS = 64, DS = 4 and 32K points, in a mixture of water and
D2O.
19F MRS Acquisition Protocol. 19F MRS experiments were
performed in a Bruker BioSpec 11.7 T magnetic resonance scanner
with 16 cm bore for small rodents (Bruker Biospin) along a 9 cm
shielded gradient insert capable of 750 mT/m. The acquisition of 19F
MRS spectra was done employing a 40 mm inner diameter 1H/19F
coil, which also allowed the acquisition of a reference proton image
before the 19F MRS spectra recording. All 19F nonlocalized spectra
were acquired without proton decoupling and applying the following
parameters: TD 4K, SW 10 ppm, 8 dummy scans, 660 averages, TR
1.8 s, and with a total acquisition time of 16 min. All spectra were
processed with zero filling, and applying an exponential line
broadening of 15 Hz. Every animal was scanned twice, that is, at 1
and 2 h after injection.
19F MRI Acquisition Protocol. 19F MRI experiments were
performed in a Bruker 70/30 Bruker Biospec 7 T magnetic resonance
scanner interfaced to an AVANCE III console and equipped with a
BGA12 imaging gradient system. The acquisition of 19F MRI images
was done employing a customized RF quadrature surface design with
two coils lying on a curve surface to fit the animal. A Butterfly
arrangement and square loops were selected to shape the quadrature
surface coil.36,37 A nonmagnetic fixed- and variable capacitors were
used to perform tuning and matching. In addition, a balun made of a
semirigid cable and a capacitor was added to minimize unwanted
common current modes.38,39 The RF quadrature surface coil was
mainly optimized to fluorine, but the coil can also be tuned for
protons, which also allowed the acquisition of a reference proton
image before the 19F MRI recording. For details of each scanning
condition, see the Supporting Information.
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